Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 5/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4858731 | 0.90 | UTS2R (0.61) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL5522586 | 0.89 | UTS2R (0.57) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL5518936 | 0.89 | UTS2R (0.61) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL5521736 | 0.89 | UTS2R (0.58) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| Hydrochloric Acid SCHEMBL5532609 | 0.88 | UTS2R (0.60) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL5515244 | 0.87 | UTS2R (0.57) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL5519337 | 0.85 | UTS2R (0.57) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL5524873 | 0.85 | UTS2R (0.61) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL5520794 | 0.84 | UTS2R (0.55) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL5519342 | 0.84 | UTS2R (0.55) | UTS2RADRA2ADRD2SLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010516-A1 | Novel piperidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-01-11 | — | — | US | claimed |
| EP-1641776-A1 | NOVEL PIPERIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-04-05 | — | — | EP | claimed |
| WO-2004099180-A1 | NOVEL PIPERIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-18 | — | — | WO | claimed |
| US-20070010516-A1 | Novel piperidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-01-11 | — | — | US | disclosed |
| US-20070010516-A1 | Novel piperidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-01-11 | — | — | US | disclosed |
| US-20070010516-A1 | Novel piperidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1641776-A1 | NOVEL PIPERIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-04-05 | — | — | EP | disclosed |
| WO-2004099180-A1 | NOVEL PIPERIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010516-A1 | Novel piperidine derivatives | UTS2R, VIPR2, NTSR2 | UTS2R 1/4885ADRA2A 35/4885DRD2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.